肺癌靶向药物-[自动保存的].pptx

; 肺癌的分子分型与靶向治疗的地位;;靶向药物作用靶位; 1 EGFR 酪氨酸激酶抑制剂（EGFR-TKI）;目前研究情况下，TKIs可能的最大预期获益人群; 1 EGFR 酪氨酸激酶抑制剂（EGFR-TKI）;1.1 第一代EGFR-TKI;1.1 第一代EGFR-TKI;1.1 第一代EGFR-TKI;1.1 第一代EGFR-TKI;1.1 第一代EGFR-TKI;1.1 第一代EGFR-TKI;1.2 第二代EGFR-TKI;1.2 第二代EGFR-TKI;1.3 第三代EGFR-TKI;2 ALK 阳性的晚期NSCLC 靶向治疗 ;N=977;概 要;2.1 第一代ALK 抑制剂;PROFILE 1001:克唑替尼首次人体试验;?PROFILE 1005:Ⅱ期单臂多中心研究;;PROFILE 1007:克唑替尼与培美曲塞或多西他赛的比较;PROFILE 1014：NEJM 2014 ;2.1 第一代ALK 抑制剂;PROFILE 1001研究;2.1 第一代ALK 抑制剂;2.2 第二代ALK 抑制剂;2.2.1 色瑞替尼（Ceritinib， 商品名Zykadia）;2.2.1 色瑞替尼（Ceritinib， 商品名Zykadia）;Objective Tumor Response (ASCEND-4);Ceritinib: ASCEND-4(WCLC);Primary Endpoint: PFS （ASCED-4）;;;Ceritinib: ASCEND-4(WCLC);Primary Endpoint: PFS （ASCED-4）;Ceritinib有较高概率的3/4级不良反应;;2.2.2 艾乐替尼艾乐替尼（Alectinib，商品名Alecensa）;Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study;2.2.2 艾乐替尼艾乐替尼（Alectinib，商品名Alecensa）;Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial;Secondary endpoint: PFS, IRC-assessed;2.2.2 艾乐替尼艾乐替尼（Alectinib，商品名Alecensa）;Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial;Secondary endpoint: PFS, IRC-assessed;PFS by baseline CNS metastases status*;Efficacy and Safety of Lorlatinib in ALK+ Non-Small Cell Lung Cancer (NSCLC) Patients (pts) With ≥1 Prior ALK Tyrosine Kinase Inhibitor (TKI): A Phase 1/2 Study;Lorlatinib – a potent ALK TKI covering the broadest range of ALK resistance mutations;Lorlatinib can cross the blood–brain barrier to achieve clinically meaningful CNS activitybr /;Phase 2 Design and Patient Populations of an Ongoing Phase 1/2 Study in ALK/ROS1+ NSCLC ;Slide 9;Confirmed Intracranial–ORR in ALK+ Patients Previously Treated With ≥1 ALK TKI;Confirmed Intracranial–ORR in ALK+ Patients Previously Treated With ≥1 ALK TKI;Confirmed CNS Responses in ALK+ Patients With Measurable Diseasea Previously Treated With ≥1 ALK T